Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Prostatic Neoplasms × ipatasertib × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Gliosarcoma 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Docetaxel 28 Prednisone 24 enzalutamide 15 pembrolizumab 10 Abiraterone Acetate 10 gallium 68 PSMA-11 8 Radiotherapy 8 Pluvicto 8 Leuprolide 7 Nivolumab 6 Magnetic Resonance Spectroscopy 6 Estramustine 6 Biopsy 5 orteronel 4 olaparib 4 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4 Specimen Handling 4 Radiotherapy, Intensity-Modulated 4 Paclitaxel 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Cyclophosphamide 4 Carboplatin 4 tremelimumab 3 durvalumab 3 darolutamide 3 cemiplimab 3 cabazitaxel 3 bicalutamide 3 avelumab 3 abiraterone 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04737109 2023-11-13

ADDItion

Big Ten Cancer Research Consortium

Phase 1/2 Terminated

6 enrolled 9 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡